AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31892263 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive health-care program (CHCP) including open lectures, health counseling, exercise classes, nutrition counseling, and self-help group meetings
Number of subjects: 58
Study 31892263 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive health-care program (CHCP)
Number of subjects: 58
Study 31892263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 58
Study 29948956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (60 mg per day)
Number of subjects: 135
Study 29948956 — intervention group
Group type: COMPARATOR
Intervention: No pyridoxine
Number of subjects: 135
Study 28920767 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum group (electroacupuncture device)
Number of subjects: 40
Study 28920767 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham device)
Number of subjects: 40
Study 25099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct EMG control
Number of subjects: 6
Study 25099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern recognition control
Number of subjects: 6
Study 25099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting from a predefined neutral posture
Number of subjects: 6
Study 25099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting from the previous posture in the sequence
Number of subjects: 6
Study 24490369 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional nursing plus health education, psychological counseling, and diet guidance (Experimental Group)
Number of subjects: 226
Study 24490369 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing (Control Group)
Number of subjects: 226
Study 21360490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg plus MTX
Number of subjects: 1196
Study 21360490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg plus MTX
Number of subjects: 1196
Study 21360490 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 1196
Study 18471512 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1-2 mg/4 hour, intravenously) and albumin (1 g/kg followed by 20-40 g/day)
Number of subjects: 46
Study 18471512 — intervention group
Group type: COMPARATOR
Intervention: Albumin alone
Number of subjects: 46
Study 18471512 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin and albumin
Number of subjects: 46
Study 17506795 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 0
Study 12921475 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 (Adderall XR) 10 mg
Number of subjects: 51
Study 12921475 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 (Adderall XR) 20 mg
Number of subjects: 51
Study 12921475 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 (Adderall XR) 30 mg
Number of subjects: 51
Study 12921475 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 10 mg (active control)
Number of subjects: 51
Study 12921475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11036846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pool exercise combined with a 6 session education program
Number of subjects: 58
Study 11036846 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 9044877 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-MIBG
Number of subjects: 8
Study 9044877 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg and 160 mg)
Number of subjects: 8
Study 8239971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Number of subjects: 19
Study 8239971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3899554 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise preceded by the usual dose of insulin
Number of subjects: 13
Study 3899554 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise preceded by one-half of the usual dose of insulin
Number of subjects: 13
Study 3899554 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise preceded by two-thirds of the usual dose of insulin
Number of subjects: 13
Study 3899554 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise without the usual dose of insulin
Number of subjects: 13
Study 3899554 — intervention group
Group type: COMPARATOR
Intervention: Resting control day
Number of subjects: 13
Study 29570607 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chocolate milk (224 kcal)
Number of subjects: 28
Study 29570607 — intervention group
Group type: EXPERIMENTAL
Intervention: cola (158 kcal)
Number of subjects: 28
Study 29570607 — intervention group
Group type: EXPERIMENTAL
Intervention: fruit drink (154 kcal)
Number of subjects: 28
Study 29570607 — intervention group
Group type: COMPARATOR
Intervention: water (control; 0 kcal)
Number of subjects: 28
Study 25640037 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 24
Study 25640037 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 24
Study 25055497 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 63
Study 25055497 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminomethylbenzoic acid
Number of subjects: 63
Study 25055497 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 63
Study 23451439 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive lateral approach
Number of subjects: 28
Study 23451439 — intervention group
Group type: COMPARATOR
Intervention: Mini-midvastus approach
Number of subjects: 28
Study 19966044 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (online training, guideline dissemination, educational sessions)
Number of subjects: 0
Study 19966044 — intervention group
Group type: COMPARATOR
Intervention: Control group (dissemination of guidelines only)
Number of subjects: 0
Study 19966044 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 0
Study 18854916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 79
Study 18854916 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox
Number of subjects: 79
Study 16019927 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-ray irradiation (60Co-gamma source)
Number of subjects: 20
Study 12196659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral albuterol for 6 months
Number of subjects: 13
Study 10503860 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF mouthrinse (0.5 microg/mL), administered for 1 minute 3 times per day after oral hygiene procedures, starting from the first day of mucositis until clinical improvement.
Number of subjects: 39
Study 10503860 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical patients with similar clinical characteristics).
Number of subjects: 39
Study 10503860 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF mouthrinse (0.5 microg/mL).
Number of subjects: 39
Study 9117817 — intervention group
Group type: EXPERIMENTAL
Intervention: Film dressing left intact until suture removal
Number of subjects: 30
Study 9117817 — intervention group
Group type: COMPARATOR
Intervention: Existing wound-care protocol of a dry dressing removed after 48 hours
Number of subjects: 30
Study 1914267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet of sublingual nitroglycerin without transdermal nitroglycerin (Group 1)
Number of subjects: 48
Study 1914267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet of sublingual nitroglycerin with 12-hour-daily intermittent therapy of transdermal nitroglycerin (Group 2)
Number of subjects: 48
Study 1914267 — intervention group
Group type: COMPARATOR
Intervention: 1 tablet of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 3)
Number of subjects: 48
Study 1914267 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 tablets of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 4)
Number of subjects: 48
Study 6349375 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 94
Study 6349375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 31524642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (neoadjuvant)
Number of subjects: 389
Study 31524642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TRG and TNM
Number of subjects: 389
Study 31524642 — intervention group
Group type: COMPARATOR
Intervention: TNM staging alone
Number of subjects: 389
Study 30286787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional guidance provided by a registered dietitian once every 3 months for a total of three sessions.
Number of subjects: 250
Study 30286787 — intervention group
Group type: COMPARATOR
Intervention: No nutritional guidance (control group).
Number of subjects: 250
Study 27281260 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS combined with CBT plus clomipramine (Group A)
Number of subjects: 360
Study 27281260 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS combined with CBT plus placebo (Group B)
Number of subjects: 360
Study 27281260 — intervention group
Group type: COMPARATOR
Intervention: Simulated (placebo) TEAS combined with CBT plus clomipramine (Group C)
Number of subjects: 360
Study 24980290 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO, 10 g)
Number of subjects: 25
Study 24980290 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (10 g)
Number of subjects: 25
Study 22810985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified complementary food (instant flour)
Number of subjects: 426
Study 22810985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified complementary food (food complement)
Number of subjects: 426
Study 22810985 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional complementary food at home)
Number of subjects: 426
Study 17497593 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 8
Study 16377602 — intervention group
Group type: EXPERIMENTAL
Intervention: Single tailored (ST) mailout of print material
Number of subjects: 4014
Study 16377602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple tailored (MT) mailouts of print materials spanning 12 months
Number of subjects: 4014
Study 16377602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple retailored (MRT) mailouts spanning 12 months
Number of subjects: 4014
Study 16377602 — intervention group
Group type: COMPARATOR
Intervention: Single untailored (SU) mailout of print material
Number of subjects: 4014
Study 12377400 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS at individual motor threshold (MT)
Number of subjects: 31
Study 12377400 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS at 90% subthreshold intensity
Number of subjects: 31
Study 12377400 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (low intensity)
Number of subjects: 31
Study 10413266 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged intermittent high‐intensity shuttle running (90 min of intermittent shuttle running and walking)
Number of subjects: 16
Study 10413266 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged intermittent high‐intensity shuttle running
Number of subjects: 16
Study 10413266 — intervention group
Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 16
Study 7766324 — intervention group
Group type: EXPERIMENTAL
Intervention: Escharectomy during shock stage (Group A)
Number of subjects: 50
Study 7766324 — intervention group
Group type: COMPARATOR
Intervention: Escharectomy after shock stage (Group B)
Number of subjects: 50
Study 2110386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (8 to 10 g/m2) with mesna uroprotection, bolus administration
Number of subjects: 154
Study 2110386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (8 to 18 g/m2) with mesna uroprotection, continuous infusion
Number of subjects: 154
Study 2110386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (up to 18 g/m2)
Number of subjects: 154
Study 2110386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (16 g/m2)
Number of subjects: 154
Study 2110386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (18 g/m2)
Number of subjects: 154
Study 2110386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide with mesna uroprotection
Number of subjects: 154
Study 2110386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 154
Study 2110386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide without mesna
Number of subjects: 154
Study 347992 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate intranasal aerosol
Number of subjects: 30
Study 31759686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cre8 amphilimus eluting stent
Number of subjects: 323
Study 31759686 — intervention group
Group type: COMPARATOR
Intervention: Taxus Liberté stent
Number of subjects: 323
Study 31179799 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified puncture method
Number of subjects: 436
Study 31179799 — intervention group
Group type: COMPARATOR
Intervention: Standard infusion puncture method (Control)
Number of subjects: 436
Study 28591198 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 45mg dose of primaquine (equivalent to three SLD PQ)
Number of subjects: 101
Study 28591198 — intervention group
Group type: COMPARATOR
Intervention: DHP-alone (no primaquine)
Number of subjects: 101
Study 28591198 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 45mg dose of primaquine
Number of subjects: 101
Study 28591198 — intervention group
Group type: COMPARATOR
Intervention: DHP-alone
Number of subjects: 101
Study 26202995 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli (1 lozenge containing Lactobacillus reuteri DSM 17938 and ATCC PTA 5289, twice daily for 12 weeks)
Number of subjects: 215
Study 26202995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 12 weeks)
Number of subjects: 215
Study 26202995 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli
Number of subjects: 215
Study 26202995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 24125608 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention in Xiacheng and Gongshu districts
Number of subjects: 2016
Study 24125608 — intervention group
Group type: COMPARATOR
Intervention: Control area (Xihu district)
Number of subjects: 2016
Study 21610270 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 661
Study 21610270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study 19388893 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 372
Study 19388893 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.05-0.1 mg/kg orally)
Number of subjects: 372
Study 19388893 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Relaxing music and Midazolam
Number of subjects: 372
Study 16455894 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha interferon 2b (IFN-alpha2b) (3 million units three times a week) + ribavirin (800 mg/day)
Number of subjects: 348
Study 16455894 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN-alpha2b (1.5 mug/kg of body weight/week) + ribavirin (800 mg/day)
Number of subjects: 348
Study 16455894 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV CA below the threshold value (4.18 log(10) pg/ml . 10(4))
Number of subjects: 348
Study 15320677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load training
Number of subjects: 26
Study 15320677 — intervention group
Group type: COMPARATOR
Intervention: High-repetition training
Number of subjects: 26
Study 11924291 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical caps and masks
Number of subjects: 1034
Study 11924291 — intervention group
Group type: COMPARATOR
Intervention: No surgical caps and masks (other group)
Number of subjects: 1034
Study 9613379 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% twice daily
Number of subjects: 40
Study 9613379 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% twice daily
Number of subjects: 40
Study 8607321 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg.kg‐1)
Number of subjects: 8
Study 8607321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2635342 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary mouth wash procedure
Number of subjects: 100
Study 2635342 — intervention group
Group type: COMPARATOR
Intervention: Sputum preceded spit
Number of subjects: 100
Study 2635342 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctly treated patients (80 subjects)
Number of subjects: 100
Study 2635342 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding of bacteria in BLA but absent in spit and/or sputum
Number of subjects: 100
Study 326034 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone therapy
Number of subjects: 28
Study 326034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 27906839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (500 mg)
Number of subjects: 13
Study 27906839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26041745 — intervention group
Group type: EXPERIMENTAL
Intervention: AC→XT (Capecitabine 825 mg/m² twice daily, days 1‐14; Docetaxel 75 mg/m² on day 1)
Number of subjects: 2611
Study 26041745 — intervention group
Group type: COMPARATOR
Intervention: AC→T (Doxorubicin and Cyclophosphamide followed by Docetaxel, T dose: 100 mg/m² on day 1)
Number of subjects: 2611
Study 26041745 — intervention group
Group type: EXPERIMENTAL
Intervention: AC→XT
Number of subjects: 2611
Study 23377341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole foam, 2%, twice daily
Number of subjects: 500
Study 22010095 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained restorations
Number of subjects: 38
Study 22010095 — intervention group
Group type: COMPARATOR
Intervention: Cemented restorations
Number of subjects: 38
Study 19801933 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 80
Study 19801933 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 80
Study 16714232 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification cataract surgery
Number of subjects: 24
Study 16113459 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (duration: 8 weeks)
Number of subjects: 470
Study 16113459 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (duration: 4 years)
Number of subjects: 470
Study 16113459 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (population: adults with asthma)
Number of subjects: 470
Study 11497388 — intervention group
Group type: EXPERIMENTAL
Intervention: NK1 receptor antagonists
Number of subjects: 0
Study 11497388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NK1 receptor antagonists with existing agents
Number of subjects: 0
Study 11497388 — intervention group
Group type: COMPARATOR
Intervention: 5-HT3 receptor antagonists
Number of subjects: 0
Study 9412749 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment by trained observers
Number of subjects: 0
Study 9412749 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual scoring of skin irritation reactions
Number of subjects: 0
Study 29324705 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan treatment (3200 mg daily)
Number of subjects: 116
Study 29324705 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 116
Study 26611240 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality game (Nintendo Wii) for cognitive enhancement, 10 sessions, 50 minutes/session, 2 days/week for 5 weeks
Number of subjects: 40
Study 25618771 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential electrical stimulation + standard urotherapy
Number of subjects: 54
Study 25618771 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy only (control)
Number of subjects: 54
Study 23408464 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 189
Study 23408464 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention (DI)
Number of subjects: 189
Study 19820280 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion-controlled diet (NutriSystem D) (PCD)
Number of subjects: 69
Study 19820280 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE) program
Number of subjects: 69
Study 17377389 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% retinaldehyde/6% glycolic acid cream (RALGA)
Number of subjects: 145
Study 17377389 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 145
Study 14685749 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 121
Study 14685749 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 121
Study 14685749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 121
Study 11226797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring segments (ICRS) implantation
Number of subjects: 110
Study 9507234 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g highly purified ethyl esters of eicosapentaenoic acid (EPA) (95% pure)
Number of subjects: 14
Study 9507234 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g docosahexaenoic acid (DHA) (90% pure)
Number of subjects: 14
Study 8028506 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial (2 hours of brisk walking at 30.9% ± 1.6% of VO2 max)
Number of subjects: 12
Study 8028506 — intervention group
Group type: COMPARATOR
Intervention: Control trial (resting the day before the test meal)
Number of subjects: 12
Study 2597658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (intra-muscular)
Number of subjects: 0
Study 2597658 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1254157 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative prophylactic chemotherapy
Number of subjects: 1022